Is Tango Therapeutics Inc (TNGX) overvalued? · $5.36B cap
Tango Therapeutics Inc (TNGX) is a biotechnology company listed on NASDAQ.
This page asks whether Tango Therapeutics Inc (TNGX) looks expensive on cached numbers — not a short thesis.
Latest reported TNGX revenue for 2026-06-30 was $0. Net income was -$100.9M. TNGX currently screens at market cap $5.36B.
TNGX currently screens at market cap $5.36B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next TNGX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the TNGX stock page for the full model, not this heading.
Not investment advice.